ALK and non-small cell lung carcinoma: Crizotinib, an ATP‐competitive, oral, small‐molecule tyrosine kinase inhibitor that targets ALK, mesenchymal–epithelial transition (MET), and ROS19, 10, has demonstrated promising efficacy and acceptable toxicity in many studies of patients with advanced NSCLC 3, 11, 12, 13, 14.